Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
NuVasive, Inc. - Common Stock
(NQ:
NUVA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NuVasive, Inc. - Common Stock
< Previous
1
2
3
Next >
Tilray To Crater Over 30%? Here Are 5 Other Price Target Changes For Friday
September 30, 2022
Barclays cut Tilray Inc (NASDAQ: TLRY) price target from $4.5 to $2. Barclays analyst Gaurav Jain maintained an Underweight rating on the stock. Tilray Brands shares rose 0.3% to $2.87 in pre-market...
Via
Benzinga
Twitter, Zoom Video And Some Other Big Stocks Moving Lower On Tuesday
August 23, 2022
GigaCloud Technology Inc. (NASDAQ: GCT) fell 29.9% to $29.01 after declining around 14% on Monday.
Via
Benzinga
NuVasive Earnings Perspective: Return On Invested Capital
May 18, 2022
According to Benzinga Pro, during Q1, NuVasive (NASDAQ:NUVA) earned $19.20 million, a 152.27% increase from the preceding quarter. NuVasive's sales decreased to $290.76 million, a 3.75% change since...
Via
Benzinga
4 Analysts Have This to Say About NuVasive
May 06, 2022
Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter:
Via
Benzinga
NuVasive: Q1 Earnings Insights
May 04, 2022
NuVasive (NASDAQ:NUVA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:10 PM. Here's what investors need to know about the announcement. Earnings NuVasive beat estimated earnings by...
Via
Benzinga
Where NuVasive Stands With Analysts
January 07, 2022
NuVasive (NASDAQ:NUVA) has observed the following analyst ratings within th...
Via
Benzinga
Earnings Scheduled For July 28, 2021
July 28, 2021
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.55 per share on revenue of $7.90 billion. • United...
Via
Benzinga
Earnings Scheduled For May 5, 2021
May 05, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Earnings Outlook For NuVasive
May 03, 2022
NuVasive (NASDAQ:NUVA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that NuVasive will...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022
March 28, 2022
Upgrades
Via
Benzinga
Health Care Stocks Could Use A Surgical Boom — Will It Happen For Stryker, Boston Scientific, Others?
March 15, 2022
Elective procedures are recovering slowly as Covid cases decline. Will they ever boom?
Via
Investor's Business Daily
NuVasive: Q4 Earnings Insights
February 23, 2022
NuVasive (NASDAQ:NUVA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Why Did BofA Securities Give Globus Medical A Double Upgrade?
December 13, 2021
Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE:
Via
Benzinga
NuVasive's Q3 Earnings Hit By COVID-19, Staff Shortage; Cuts FY21 Guidance
November 10, 2021
NuVasive Inc (NASDAQ: NUVA) reported Q3 net sales of $270.8 million, an 8.3% decrease on a reported and constant currency basis, missing the consensus of $291.79...
Via
Benzinga
Exposures
COVID-19
Earnings Scheduled For February 23, 2022
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
NuVasive, Inc (NUVA) Q3 2021 Earnings Call Transcript
November 10, 2021
NUVA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:
Via
Benzinga
NuVasive: Q3 Earnings Insights
November 09, 2021
NuVasive (NASDAQ:NUVA) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NuVasive...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 13, 2021
Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The market value of their outstanding shares is at $...
Via
Benzinga
This Revolutionary Medical Device Company Goes to 11
August 13, 2021
To stand tall against a competitive market, NuVasive depends on a strong spinal platform.
Via
The Motley Fool
Exposures
COVID-19
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
August 02, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
NuVasive, inc (NUVA) Q2 2021 Earnings Call Transcript
July 28, 2021
NUVA earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
FDA Flags Certain Biocompatibility Concerns For NuVasive's Orthopedics' Precice Devices
July 09, 2021
The FDA informed healthcare providers of potential biocompatibility concerns with NuVasive Inc's (NASDAQ:
Via
Benzinga
Exposures
Product Safety
NuVasive Inc (NUVA) Q1 2021 Earnings Call Transcript
May 06, 2021
NUVA earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.